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Abstract
Schizophrenia (SCZ) is a severe, debilitating mental illness which has a significant
genetic component. The identification of genetic factors related to SCZ has been
challenging and these factors remain largely unknown. To evaluate the contribution
of de novo variants (DNVs) to SCZ, we sequenced the exomes of 53 individuals
with sporadic SCZ and of their non-affected parents. We identified 49 DNVs, 18 of
which were predicted to alter gene function, including 13 damaging missense
mutations, 2 conserved splice site mutations, 2 nonsense mutations, and 1
frameshift deletion. The average number of exonic DNV per proband was 0.88,
which corresponds to an exonic point mutation rate of 1.761028 per nucleotide per
generation. The non-synonymous-to-synonymous mutation ratio of 2.06 did not
differ from neutral expectations. Overall, this study provides a list of 18 putative
candidate genes for sporadic SCZ, and when combined with the results of similar
reports, identifies a second proband carrying a non-synonymous DNV in the
RGS12 gene.
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PLOS ONE | DOI:10.1371/journal.pone.0112745 November 24, 2014

1 / 12

De Novo Mutations in Schizophrenia

Introduction
Schizophrenia (SCZ) is a severe mental illness that has a population prevalence of
0.4 to 0.8% [1]. Individuals with SCZ experience psychosis, poor social
functioning, and cognitive impairments. SCZ is a highly heritable disorder
encouraging research into the genetic component of the disorder [2]. Large
genome-wide studies have recently suggested that common single nucleotide
polymorphisms (SNPs) collectively account for at least 32% of the variance in
SCZ liability [3, 4, 5, 6]. Rare copy number variants (CNVs) have also been shown
to contribute to SCZ risk [7, 8, 9, 10]. Despite these encouraging advances, many
of the genetic components of the disease await identification. Besides inherited
variants, new mutations may also contribute to risk.
A sizeable proportion of SCZ patients do not have a family history of the
disease and it has been hypothesized that de novo variants (DNVs) could account
for some of these sporadic cases [11]. Several lines of evidence support this
hypothesis. Firstly, despite the markedly reduced reproductive rate among SCZ
patients, the prevalence of the disorder has remained constant in the general
population (0.4–0.8%) [12]. DNVs, which are not subject to negative selection,
provide an explanation for risk alleles remaining frequent in the population.
Secondly, it has been shown that DNV load correlates with paternal age [13],
which could explain why older males who have accumulated new mutations are
more likely than younger males to father schizophrenic children [14]. Thirdly,
DNVs tend to be more deleterious to gene function than inherited ones because
they have not been subjected to evolutionary selection (with the exception of
mutations incompatible with life) and are thus disease-prone [15]. Consistently,
individuals with sporadic SCZ carry significantly more de novo CNVs than do
controls, whereas individuals with familial SCZ do not [16]. However, subsequent
studies confirming a higher rate of de novo CNVs among individuals with SCZ
compared with controls did not reveal a significant difference between individuals
with sporadic or familial SCZ [17, 18].
It has become evident that some fraction of disease alleles may occur as de novo
events. With recent advances in high-throughput sequencing technologies, one
can now identify a considerable fraction of de novo variation, including single
nucleotide variants (SNVs) and small insertions/deletions (indels), thus increasing
the proportion of disease risk that can be explained. Five studies have analyzed the
contribution of de novo variants in sporadic cases of SCZ [19, 20, 21, 22, 23].
Collectively, these studies reported a mutation rate of ,1.561028 mutation per
base per generation, which is consistent with neutral expectations. Regarding the
burden of protein-altering variants, some discrepancies exist among these studies.
Indeed, Xu et al. (2011 & 2012) observed that individuals with SCZ exhibited a
significantly higher ratio of non-synonymous-to-synonymous SNVs compared
with controls, whereas Fromer et al. (2014) did not find any significant
enrichment.
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Here, we further explored the contribution of DNVs to the etiology of sporadic
SCZ by sequencing the exomes of 53 affected individuals and of their healthy
parents.

Results
Schizophrenia trios
Fifty-three individuals with sporadic SCZ (39 males and 14 females) and their
unaffected parents were recruited. More than half of the patients had a diagnosis
of paranoid schizophrenia (n531; 58.4%). The remaining patients had a diagnosis
of undifferentiated schizophrenia (n56, 11.3%), non-organic schizophrenia
(n55; 9.4%), disorganized schizophrenia (n55, 9.4%), schizoaffective disorder
(n55, 9.4%), or simple schizophrenia (n51; 1.9%). The average age at disease
onset was 21.03 years. (Text S1 and Table S1).

Exome sequencing data
Exome sequencing was conducted for 159 individuals. On average, 206 (¡78 SD)
million reads were produced per sample. Of these, 198 (¡76 SD) million mapped
to the reference genome (hg19). After the removal of duplicate reads, 150 (¡51
SD) million reads remained. Among these reads, 113 (¡40 SD) million were ontarget. These reads represented an average coverage of at least 86 for 95.01%
(¡4.8 SD) of the coding portion of the RefSeq genes. On average, 24,401 (¡1,407
SD) variants were detected per individual. Table S2 summarizes the exome
sequencing results for each individual.

Identification of damaging de novo variants
In our cohort of 53 proband-parent trios, we identified 47 exonic and 2 intronic
conserved splice site DNVs, which were not previously reported in any public SNP
database (Table 1). The observed rate of de novo events in the RefSeq proteincoding exons was 0.88, corresponding to an exonic point mutation rate of
1.761028, in accord with previous reports [21, 24, 25, 26, 27]. The distribution of
the number of DNVs per trio did not differ from the Poisson distribution (Chisquare goodness of fit test: p50.42; Figure S1). Father’s age at childbirth had no
significant effect on the number of DNVs in the offspring (R250.0113; p50.44;
Figure S2A). However, when we separated the father according to the median age
at childbirth, we observed a trend towards more DNVs in the children of the
oldest fathers (0.79 and 1.08 DNVs in the offspring of the youngest (19–29 years
old) and the oldest (30–52 years old) fathers, respectively; one-tailed Student’s tTest; p50.097; Figure S2B).
In addition, we observed four instances of variant alleles being present at low
frequencies, ranging from 14 to 21% of reads, indicative of somatic mosaicism in
blood cells. We found one nonsense mutation (p.K854X) in DSG3 and three
missense mutations: p.S1006F in NLRP11, p.G1352D in LRRC7, and p.R1177C in
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Table 1. List of the 49 validated de novo variants.
Proband_ID

Gene Name

Gene ID

Mutation type

Nucleotide change

AA change

SIFT

PP2

MT
0.35

98708

AHDC1

NM_001029882

missense

c.C1459T

p.R487W

0.00

0.99

BUZ_406

C5orf4

NM_032385

missense

c.G893A

p.G298E

0.00

1.00

1.00

SZP_trio26.P

C9orf172

NM_001080482

missense

c.G2855T

p.C952F

0.00

1.00

0.99

SP-226

DDX20

NM_007204

missense

c.G163C

p.D55H

0.00

1.00

0.99

15LE-p

KDM3B

NM_016604

missense

c.C4216T

p.R1406W

0.00

1.00

1.00

360

LRRC4

NM_022143

missense

c.C327G

p.N109K

0.00

1.00

0.99

12JC-p

PSMC2

NM_002803

missense

c.G597T

p.E199D

0.02

0.55

1.00

98768

QSER1

NM_001076786

missense

c.T4100C

p.I1367T

0.00

0.77

0.07

SP-227

RGS12

NM_198227

missense

c.G161T

p.R702L

0.08

1.00

1.00

SP-240

SLC22A23

NM_015482

missense

c.T734G

p.L245R

0.00

1.00

0.99

6TP-p

TMEM8C

NM_001080483

missense

c.C184T

p.R62C

0.02

1.00

0.02

2142

USP10

NM_005153

missense

c.C2197T

p.R733W

0.00

1.00

0.99

98757

FAM189A2

NM_001127608

missense

c.C478T

p.P160S

0.09

1.00

0.70

2256

CHD5

NM_015557

missense

c.G3943A

p.V1315M

0.07

0.92

0.26

2150

CILP2

NM_153221

missense

c.G1040A

p.R347Q

0.26

0.41

0.02

88536

DOT1L

NM_032482

missense

c.G2509A

p.A837T

0.81

0.00

0.09

SP-245

HPCA

NM_002143

missense

c.G334A

p.G112S

0.13

0.00

1.00

2262

KDELC2

NM_153705

missense

c.A539G

p.K180R

0.32

0.06

0.00

SZP_trio27.P

KIAA0430

NM_001184998

missense

c.A340C

p.M114L

0.12

0.47

0.01

2265

KIF24

NM_194313

missense

c.G865A

p.V289I

0.07

0.46

0.99

98768

KMO

NM_003679

missense

c.G1381T

p.A461S

0.37

0.00

0.00

SZP_trio26.P

MYLPF

NM_013292

missense

c.G244A

p.V82I

0.11

0.01

0.99

400

PITRM1

NM_001242309

missense

c.A2129G

p.K710R

0.46

0.48

0.95

SZP_trio28.P

SHARPIN

NM_030974

missense

c.T427C

p.S143P

0.17

0.99

0.02

15LE-p

SLC22A9

NM_080866

missense

c.T427A

p.S143T

0.18

0.02

0.00

2265

SNX19

NM_014758

missense

c.G2128A

p.E710K

0.22

0.42

0.12

12JC-p

SYNE1

NM_033071

missense

c.A19898T

p.Q6633L

1.00

0.13

0.03

2145

TIGD7

NM_033208

missense

c.G48A

p.M16I

0.07

0.18

0.01

1.00

0.01

NA

2150

ZNF844

NM_001136501

missense

c.A1559G

p.K520R

18 (3) proband

MAP4K4

NM_001242559

nonsense

c.C1795T

p.R599X

98706

CHRNG

NM_005199

nonsense

c.C511T

p.Q171X

SP-236

EIF3B

NM_001037283

splice site

c.2029-1G.C

88185

SETD1A

NM_014712

splice site

c.4582delAG.-

2148

FN1

NM_002026

frameshift

c.G277_del

p.A93LfsX26

233

AJUBA

NM_032876

synonymous

c.T852G

p.L284L

SZP_trio28.P

ALG11

NM_001004127

synonymous

c.C306T

p.T102T

404

ANKRD44

NM_001195144

synonymous

c.C882T

p.N294N

2254

ARHGAP11A

NM_014783

synonymous

c.C1746T

p.S582S

403

ARRB2

NM_001257331

synonymous

c.G483A

p.P161P

TON_078

CELF5

NM_021938

synonymous

c.C1359T

p.S453S

SP-227

FOXO1

NM_002015

synonymous

c.G135C

p.S45S

SP-226

NCKAP5

NM_207363

synonymous

c.C4398G

p.A1466A

360

NHSL2

NM_001013627

synonymous

c.C2341T

p.L781L

98428

ORMDL1

NM_001128150

synonymous

c.G300A

p.K100K
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Table 1. Cont.
Proband_ID

Gene Name

Gene ID

Mutation type

Nucleotide change

AA change

392

OXA1L

NM_005015

synonymous

c.C591T

p.G197G

403

PRRC2B

NM_013318

synonymous

c.G5880A

p.P1960P

2142

RALGDS

NM_001042368

synonymous

c.C1446T

p.T482T

SP-236

TIMP2

NM_003255

synonymous

c.C651T

p.I217I

SZP_trio26.P

TMEM55B

NM_001100814

synonymous

c.G300A

p.V100V

SIFT

PP2

MT

SIFT 5 Sorting Intolerant from Tolerant algorithm, PP25 Polyphen2, MT 5 Mutation Taster. In silico prediction scores shaded in grey are considered as
damaging.
doi:10.1371/journal.pone.0112745.t001

CC2D2A. These 4 events were confirmed by Sanger sequencing, which showed a
similar level of allelic imbalance (Figure S3). As these post-zygotic mutations were
not necessarily present in the brain of the patients, we did not analyze them
further.
Among the 49 DNVs, we discovered 15 synonymous and 34 protein-altering
DNVs, including 29 missense mutations, 2 nonsense mutations, 2 conserved
splice-site mutations, and 1 frameshift insertion/deletion. The non-synonymousto-synonymous mutation ratio of 2.06 was similar to neutral expectations (2.23)
[28]. We did not observe a significant increase in the relative rate of loss-offunction-to-missense mutations in our cohort when compared to controls from
published data sets [21, 22, 24, 26, 29, 30] (0.17 versus 0.13, respectively; X-squared
50.0765, p-value 50.78). The transition-to-transversion ratio for coding
sequences was 2.61, consistent with neutral expectations [31]. Thirteen out of 29
missense DNVs were classified as damaging by at least 2 of the 3 prediction
algorithms used (SIFT, Polyphen2 and Mutation Taster) (Table 1). Among the
nonsense mutations, the first creates a stop codon at residue 599 of the MAP4K4
protein, which would result in a truncation mutant lacking the 617 C-terminal
amino acids (1273, R599X). The second nonsense mutation is in codon 171 of the
CHRNG gene, which would result in a truncation mutant lacking the 376 Cterminal amino acids (517, Q171X). Concerning the splice site mutations, both
affect a conserved ‘‘AG’’ dinucleotide of an acceptor site, one within intron 14 of
the EIF3B gene and the other within intron 15 of the SETD1A gene; both are
predicted to significantly impact normal splicing (Table S3). Finally, the indel
variant corresponds to a single-nucleotide deletion in the FN1 gene, resulting in a
frameshift at Ala93 and a premature stop codon after the introduction of 26
amino acids. The FN1 gene produces multiple protein isoforms, the shortest of
which contains 657 amino acids (NM_054034.2). Globally, 36% of the DNVs
identified in this study (18 out of 49) were predicted as damaging (missense) or
loss-of-function (nonsense, conserved splice site and frameshift variants).
We did not observe genes recurrently mutated in our cohort. However, when
data from all available studies (including ours) were combined [19, 20, 21, 22, 23],
21 genes were found to be recurrently mutated with likely damaging DNVs trios
(Table S4). Among these 21 genes, 13 were found to carry non-synonymous de
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novo SNVs. We then determined the probability of such de novo events occurring
in these 13 genes based on each gene-specific mutation rate and the total number
of non-synonymous de novo SNVs observed across all five datasets (1,020 SCZ
trios). The number of DNVs observed in these 13 genes was in agreement with the
null expectation (Table 2). As splice-site mutations and indels were not accounted
for in the mutability calculation, we did not determine the probability of
observing multiple events in genes carrying these types of mutations. This analysis,
using data from all available studies, revealed a short list of 21 candidate genes,
among which some may be confirmed as true risk genes upon the analysis of
additional sporadic cases.
Functional in silico analysis of 375 genes affected by protein-altering de novo
variants (missense predicted as probably damaging by Polyphen, nonsense,
Table 2. Probability of occurrence of the observed number of DNVs in genes recurrently hit by non-synonymous de novo SNVs.
Study

Chr.

Mutation

Gene

AA substitution

p-value*

Gulsuner_2013

22

Missense

CACNA1I

p.797T.M

6.41 x 1023

Gulsuner_2013

22

Missense

CACNA1I

p.1311R.H

Fromer_2014

5

Missense

CD14

p.152V.M

Fromer_2014

5

Missense

CD14

p.27L.M

Karayiorgou_2012

1

Missense

DPYD

p.539G.R

Karayiorgou_2012

1

Nonsense

DPYD

p.621W.*

Fromer_2014

X

Missense

HUWE1

p.4237R.C

Fromer_2014

X

Missense

HUWE1

p.326A.G

Gulsuner_2013

4

Nonsense

KIAA1109

p.2439Q.*

Karayiorgou_2012

4

Missense

KIAA1109

p.4950Y.D

Fromer_2014

11

Missense

KIF18A

p.188V.I

Fromer_2014

11

Missense

KIF18A

p.20P.L

Fromer_2014

1

Missense

LPHN2

p.372P.R

Fromer_2014

1

Nonsense

LPHN2

p.803R.*

Fromer_2014

10

Nonsense

MKI67

p.372R.*

Gulsuner_2013

10

Nonsense

MKI67

p.857K.*

Fromer_2014

2

Nonsense

NEB

p.639Y.*

Gulsuner_2013

2

Missense

NEB

p.7908T.M

Fromer_2014

1

Missense

NIPAL3

p.172V.M

Fromer_2014

1

Nonsense

NIPAL3

p.398R.*

This study

4

Missense

RGS12

p.702R.L

Karayiorgou_2012

4

Missense

RGS12

p.1120P.L

Fromer_2014

15

Missense

RYR3

p.2205V.M

Fromer_2014

15

Missense

RYR3

p.4730I.T

Fromer_2014

17

Missense

STAC2

p.3E.K

Karayiorgou_2012

17

Missense

STAC2

2.01 x 1024
5.8 x 1024
1.18 x 1022
9.3 x 1023
2.7 x 1024
9.01 x 1024
5.01 x 1023
3.2 x 1022
1.3 x 1024
2.06 x 1023
1.32 x 1022
1.71 x 1024

p.110L.P
26

*Level of statistical significance after Bonferroni correction was set at 0.05/18.00052.70610
(18,0005 number of RefSeq genes used).

.

doi:10.1371/journal.pone.0112745.t002
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conserved splice site (¡2) and frameshift Indels) [20, 21, 22, 23] and this study
(Table S5) revealed a marginally significant enrichment for genes involved in
cellular component morphogenesis (GOTERM_BP_FAT Gene Ontology,
Benjamini p-value 53.161022) and genes expressed in brain tissues (TISSUE
Expression, Benjamini p-value 55.461028).

Discussion
Similar to other studies [19, 20, 21, 22, 23], we used whole-exome sequencing to
estimate the contribution of protein-altering de novo mutations to sporadic SCZ
and to identify susceptibility genes. Our study reveals that 34% of the sporadic cases
analyzed (18 out of 53 cases) carried a predicted damaging de novo variant, and our
results provide a list of 18 putative candidate genes. The average number of exonic
DNV per proband was 0.88, which corresponds to an exonic point mutation rate of
1.761028 per nucleotide per generation. The non-synonymous-to-synonymous
and loss-of-function-to-missense ratios did not differ from expectations or from
those of controls, suggesting no difference in mutational processes in sporadic cases
of schizophrenia. In a recent paper, Kong et al. (2012) reported on the importance
of father’s age on the risk of disease, including SCZ [13]. This group convincingly
showed that the number of de novo mutations in one offspring can be explained by
the father’s age at childbirth. We did not observe any positive correlation between
these two variables, probably owing to the limited size of our sample and the range
of the fathers’ ages at childbirth (Figure S2A,B).
Considering all five of the above-mentioned studies, 1,020 SCZ trios have been
sequenced, and 21 genes were found mutated in more than one SCZ-affected
individual (Table S4). Among these 21 genes, RGS12 was found mutated in this
study (Table 2). At this stage, none of these genes can be considered definitive risk
genes for SCZ, as the recurrence of DNVs is not significant after genome-wide
correction (Table 2). Because the estimated mutation rate for indels is less
accurate than for SNVs, we did not calculate the probability of observing such
events in LAMA2. However, the fact that there are 3 occurrences of probably
damaging DNVs in this gene makes it a candidate for SCZ risk. Larger samples
size will be required to unequivocally identify true risk variants in specific genes.
Functional in silico analysis of 375 genes affected by protein-altering de novo
variants revealed a significant enrichment in genes expressed in brain tissues and
genes involved in cellular component morphogenesis. These preliminary results
suggest that genes involved in neuronal morphogenesis could be relevant for the
altered neurodevelopmental processes in schizophrenia [32]. Among the 18
candidate genes identified in our study, RGS12 has emerged as one of the most
interesting candidates in this neurodevelopmental context, as RGS12 is known to
coordinate the Ras-dependent signals required for promoting and/or maintaining
neuronal differentiation [33], a process that is perturbed in schizophrenic patients
[32]. The RGS12 gene encodes a member of the ‘regulator of G protein signaling’
(RGS) gene family [34]. In PC12 cells and primary dorsal root ganglion neurons,
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RGS12 sustains nerve growth factor (NGF)-driven ERK activity and, therefore,
neurite outgrowth by scaffolding a complete MAPK cascade, including the NGFreceptor TrkA, activated H-Ras, B-Raf, MEK2, and ERK proteins [33]. In
addition, RGS12 is observed to be among the most down-regulated proteins in
sensory-deprived barrel cortex synapses, suggesting that it may participate in the
molecular mechanisms of sensory development [35].

Methods and Materials
Schizophrenia trios
The schizophrenia trios (case and healthy parents) were collected at 5 different
psychiatric hospitals (Text S1). In each of the families selected, the proband had a
diagnosis of schizophrenia, schizoaffective disorder or non-organic psychosis
based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
Families for which we could not exclude the presence of psychosis, major
depression, bipolar disorder, autism, mental retardation, learning and developmental delays, multiple hospitalizations in psychiatric units, or any somatic
disorders in first and second-degree relatives were not considered. This research
project was approved by the ethics committee of all participating centers (Ethics
committee of the University Hospitals of Geneva). All participants or legally
authorized representatives provided their written informed consent.

DNA extraction and exome sequencing
Genomic DNA extracted from blood was used except for sample SP-226-003
(Mother), whose DNA was extracted from lymphoblastoid cell line. Whole
genome amplification was performed on DNA from SP-198-003 (Mother) and
16(1)-Father using the REPLI-g Mini Kit (Qiagen). Exome capture was conducted
using the SureSelect Human ALL Exon kits (Agilent Technologies). Highthroughput sequencing was performed on a HiSeq2000 (Illumina). Fastq files
were processed by our ‘‘in-house’’ pipeline running on the Vital-IT (http://www.
vital-it.ch) Center for high-performance computing of the Swiss Institute of
Bioinformatics (SIB) [36].

Identification of de novo variants
De novo variants were identified using VariantMaster [36]. Practically, heterozygous variants detected in the proband with SAMtools and PINDEL quality
scores 100 and 600, respectively were retained for subsequent analysis. These
variants were filtered so as to exclude variants with a MAF.0.01 in dbSNP
(http://www.ncbi.nlm.nih.gov/SNP/), 1000Genomes [37], and Exome Variant
Server (EVS, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL:
http://evs.gs.washington.edu/EVS/)), and variants found within segmental
duplications. VariantMaster utilizes the raw (BAM) data to robustly estimate the
conditional probability of a variant to be present in the parents. All variants
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classified as de novo by VariantMaster, were subsequently visually inspected using
the SAMtools text alignment viewer. Finally, these candidate variants were
validated using Sanger sequencing on each family member. The validation rate
was at 100% for the SNVs. Most PINDEL calls classified as de novo were rejected
during visual inspection mainly due to miscalling of indels in homopolymer tracts
or trinucleotide repeats.

Statistical analysis
The mutation rate (M) of each of the RefSeq gene was calculated by adding up
mutation rates of each nucleotide taking into account the mutation rates at CpG
and non-CpG sites [13].
We used a germline mutation rate of (i) 6.1861028 per base per generation for
transition at non-CpG sites, (ii) 1.1261027 per base per generation for transition
at CpG sites, (iii) 3.7661029 per base per generation for transversion at CpG site
and (iv) 9.5961029 per base per generation for transversion at CpG sites.
Accordingly, the probability of finding a single mutation in a gene G was
MG
where (G) is the set of all captured genes. Thus, the probability of
PG ~ P
Mi
i[fGg

finding N mutations out of 667 DNVs (number of non-synonymous DNVs
observed across this and previously published studies [19, 20, 21, 22, 23] on a
specific gene G can be calculated by the binomial distribution:


667 N
PG (1{PG )667{N . Independently, we may also evaluate the
PG (N)~
N
probability of these N mutations in G to be non-synonymous. For each amino
acid Ai , the number of non synonymous mutations can be easily calculated as
32 {#Ai where #A is the number of codons coding for the amino acid A. Thus,
the probability that a mutation in a gene with coding sequence fA1 ,:::::,AL g will
L
1X
32 {#Ai
. For each gene, the final P
be non-synonymous is PG (nonsyn)~
L i
32
value is calculated as PG (N):PG (nonsyn)N .

Functional In Silico Analysis
Functional annotation of genes carrying protein-altering de novo variants was
performed by Gene Ontology analysis, using a modified Fisher’s exact test with
Benjamini correction for multiple testing as implemented in DAVID (http://
david.abcc.ncifcrf.gov/).

Supporting Information
Figure S1. Rootogram of frequency distribution of de novo events per proband.
doi:10.1371/journal.pone.0112745.s001 (DOCX)
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Figure S2. A) Age of the father and number of DNVs; B) Average number of de
novo variants (DNVs) according to paternal age.
doi:10.1371/journal.pone.0112745.s002 (DOCX)
Figure S3. Validated cases of somatic mosaic events.
doi:10.1371/journal.pone.0112745.s003 (DOCX)
Table S1. Clinical data for each SCZ trio.
doi:10.1371/journal.pone.0112745.s004 (DOCX)
Table S2. Summary of exome sequencing data.
doi:10.1371/journal.pone.0112745.s005 (DOCX)
Table S3. Human Splice Finder (HSF) prediction scores for conserved splice
site mutations.
doi:10.1371/journal.pone.0112745.s006 (DOCX)
Table S4. List of genes hit at least twice by likely damaging DNVs across all five
studies (Girard et al. 2011, Xu et al. 20122, 2012, Gulsuner et al. 2012, Fromer
et al. 2014, and this study).
doi:10.1371/journal.pone.0112745.s007 (DOCX)
Table S5. List of genes carrying de novo protein-altering mutations as reported
by Girard et al. (2011), Xu et al. (2012), Gulsuner et al. (2014 and Fromer et al.
(2014) and the present study.
doi:10.1371/journal.pone.0112745.s008 (DOCX)
Text S1. Detailed sample characteristics.
doi:10.1371/journal.pone.0112745.s009 (DOCX)
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